Selective estrogen receptor modulator

Selective estrogen receptor modulator
Drug class
Tamoxifen, a nonsteroidal triphenylethylene antiestrogen and a widely used drug in the treatment of breast cancer.
Class identifiers
SynonymsSERM; Estrogen receptor agonist/antagonist; ERAA
UseBreast cancer, infertility, osteoporosis, vaginal atrophy, dyspareunia, contraception, male hypogonadism, gynecomastia, breast pain, others
ATC codeG03XC
Biological targetEstrogen receptor
Legal status
In Wikidata

Selective estrogen receptor modulators (SERMs), also known as estrogen receptor agonists/antagonists (ERAAs),[1][2] are a class of drugs that act on estrogen receptors (ER).[3] Compared to pure ER agonists-antagonists (e.g., full agonists and silent antagonists), SERMs' activity is more tissue-specific, allowing them to selectively inhibit or stimulate estrogen-like action in various tissues.

  1. ^ Hirsch HD, Shih E, Thacker HL (June 2017). "ERAAs for menopause treatment: Welcome the 'designer estrogens'". Cleve Clin J Med. 84 (6): 463–470. doi:10.3949/ccjm.84a.15140. PMID 28628428.
  2. ^ Archer DF (August 2020). "Ospemifene: less venous thrombosis than other selective estrogen receptor modulators in postmenopausal women with vulvo vaginal atrophy". Menopause. 27 (8): 846–847. doi:10.1097/GME.0000000000001600. PMID 32576803. S2CID 220045301.
  3. ^ Riggs BL, Hartmann LC (Feb 2003). "Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice". The New England Journal of Medicine. 348 (7): 618–29. doi:10.1056/NEJMra022219. PMID 12584371.

From Wikipedia, the free encyclopedia · View on Wikipedia

Developed by Tubidy